Review
Accepted on 21 Jul 2025
Gut-Lung Axis in Allergic Asthma: Microbiota-Driven Immune Dysregulation and Therapeutic Strategies
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1617546
Type at least 3 characters
634 articles
Review
Published on 16 Jul 2025
Mapping the oxidative landscape in cystic fibrosis: methodological frontiers and application
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1632924
- 381 views
Original Research
Accepted on 14 Jul 2025
The first step for understanding the molecular mechanism of the antifibrotic effect of inhalations with 25(OH)-Vitamin D3 and 1,25(OH)2-Vitamin D3 in the murine model of hypersensitivity pneumonitis
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1610165
Original Research
Accepted on 10 Jul 2025
Quercetin ameliorates epithelial-mesenchymal transition and inflammation by targeting FSTL1 and modulating the NF-ÎşB Pathway in pulmonary fibrosis
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1594757
- 188 views
Original Research
Published on 10 Jul 2025
EPA-lactone derivative, 5,6-diHETE lactone, improves pulmonary arterial hypertension in a monocrotaline-induced model
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1621030
- 572 views
Original Research
Published on 09 Jul 2025
Novel mitophagy inducer TJ0113 alleviates pulmonary inflammation during acute lung injury
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1590458
- 455 views
Case Report
Published on 09 Jul 2025
Case Report: Coadministration of TNF-α blockade as an effective adjunctive strategy in the treatment of ANCA-negative EGPA with refractory peripheral neuropathy
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1555377
- 342 views
Original Research
Accepted on 04 Jul 2025
Active Surveillance of Adverse Drug Events in Hospitalized Patients with Pulmonary Arterial Hypertension Based on the Global Trigger Tool
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1533634
- 160 views
Original Research
Accepted on 04 Jul 2025
Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Mepolizumab and BAT2606 in Healthy Chinese Men in a Double-blinded, Randomized, Single-dose, Three-arm Parallel-group Phase I Trial
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1580883
- 189 views
Original Research
Accepted on 04 Jul 2025
THE EFFECTS OF BENRALIZUMAB ON LUNG VOLUME CHANGES DURING EXERCISE IN EXPERIMENTAL SETTING IN SEVERE ASTHMATICS: A PILOT STUDY
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1611168
- 160 views
Editorial
Published on 03 Jul 2025
Editorial: Use of bioactives for treatment of respiratory diseases
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1630486
- 579 views
Case Report
Published on 02 Jul 2025
Case Report: Omalizumab combined with voriconazole for the treatment of ABPA complicating IPA: a case report
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1588182
- 710 views
Review
Published on 26 Jun 2025
Oxidative stress in ARDS: mechanisms and therapeutic potential
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1603287
- 1,347 views
Case Report
Published on 25 Jun 2025
Case Report: Polymyxin B-induced anaphylactic shock
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1594127
- 551 views
Original Research
Published on 25 Jun 2025
Role and mechanism of IGFBP5 in the real-ambient particulate matter exposure-induced chronic lung injury
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1604301
- 532 views
Original Research
Published on 19 Jun 2025
Drug-related problems in elderly patients with AECOPD and pharmaceutical intervention practice: a prospective study
in Respiratory Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1596795
- 739 views